Jung-Chen Su

Jung-Chen Su

Auto-generated profile, based on publicly available information

Jung-Chen Su

Department of Pharmacy, National Yang Ming Chiao Tung University, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

12 April 2022 in Molecular Oncology
Verified
Journal Article
Open access
HTHsing‐I Tseng
Hsing‐I Tseng
YZYi‐Siang Zeng
Yi‐Siang Zeng
YLYing‐Chung Jimmy Lin
Ying‐Chung Jimmy Lin
JHJui‐Wen Huang
Jui‐Wen Huang
CLChih‐Lung Lin
Chih‐Lung Lin
JSJung‐Chen Su
Jung‐Chen Su
Hepatocellular carcinoma (HCC) is characterized by rapid growth, early vascular invasion, and high metastasis. Currently available US Food and Drug Administration (FDA)‐approved drugs show low therapeutic efficacy, limiting HCC treatment to chemotherapy. We designed and synthesized a novel small molecule, SCT‐1015, that allosterically activated adenosine monophosphate‐activated protein kinase (AMPK) to suppress the aerobic glycolysis in HCC. SCT‐1015 was shown to bind the AMPK α and β‐subunit interface, thereby exposing the kinase α domain to the upstream kinases, resulting in the increased AMPK activity. SCT‐1015 dramatically reduced HCC cell growth in vitro and tumor growth in vivo. We further found that AMPK formed protein complexes with hypoxia‐inducible factor 1‐alpha (HIF1α) and that SCT‐1015‐activated AMPK promoted hydroxylation of HIF1α (402P and 564P), resulting in HIF1α degradation by the ubiquitin‐proteasome system. With declined HIF1α abundance, many glycolysis‐related enzymes were downregulated, suppressing aerobic glycolysis, and promoting oxidative phosphorylation. These results indicated that SCT‐1015 channeled HCC cells into an unfavorable metabolic status. Overall, we reported SCT‐1015 as a direct activator of AMPK signaling that held therapeutic potential in HCC.

19 October 2025 in The Plant Cell
Verified
Journal Article
Closed access
PSPeng Shuai
Peng Shuai
JHJo-Wei Allison Hsieh
Jo-Wei Allison Hsieh
CKChung-Ting Kao
Chung-Ting Kao
CHChen-Wei Hu
Chen-Wei Hu
RWRay Wang
Ray Wang
YLYing-Chung Jimmy Lin
Ying-Chung Jimmy Lin
Secondary growth is a key characteristic evolved from seed plants and generates secondary xylem—the most abundant tissue on Earth. Recent studies have uncovered xylem developmental lineages in eudicots and magnoliids of angiosperms. However, xylem development in gymnosperms, the other representative clade of seed plants, remained elusive. We performed single-cell transcriptomics for xylem cells of conifers (Cunninghamia lanceolata), the major clade in gymnosperms. Using Seurat and scVI-based cross-species integration, we reconstructed the xylem differentiation trajectories and revealed that the radial system is conserved across seed plants, while the axial system in C. lanceolata exhibits a composite lineage architecture resembling both eudicots and magnoliids. To validate these trajectories, we established a multi-modal spatial framework incorporating spatial transcriptomics, spatial proteomics, and spatial metabolomics. These three spatial layers provided orthogonal evidence confirming cell-type identities and trajectory inference. Additionally, we identified a xylem cell population unique to gymnosperms, suggesting a lineage-specific specialization. Together, our findings uncover a more complex ancestral xylem architecture in gymnosperms and propose a progressive simplification of axial developmental programs from gymnosperms to angiosperms, highlighting a trajectory of reductive evolution in seed plant vascular development.

11 December 2023 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
LCLing-Han Chen
Ling-Han Chen
MLMan-Yi Lin
Man-Yi Lin
HLHsueh-Chun Lin
Hsueh-Chun Lin
FYFan-Wei Yang
Fan-Wei Yang
Hsiao-Wei LiaoHsiao-Wei Liao
Hsiao-Wei Liao
JSJung-Chen Su
Jung-Chen Su
A tricyclic core derivative, SW33, showed potency against intracellular drug-resistant strains of S. typhimurium and other intracellular pathogens with no toxicity, indicating a broad-spectrum activity against intracellular bacteria.

12 September 2024 in New Phytologist
Verified
Journal Article
Closed access
CKChung‐Ting Kao
Chung‐Ting Kao
FYFan‐Wei Yang
Fan‐Wei Yang
MWMeng‐Chen Wu
Meng‐Chen Wu
THTzu‐Huan Hung
Tzu‐Huan Hung
CHChen‐Wei Hu
Chen‐Wei Hu
JSJung‐Chen Su
Jung‐Chen Su

5 February 2024 in Archiv der Pharmazie
Verified
Journal Article
Open access
FYFan‐Wei Yang
Fan‐Wei Yang
TMTe‐Lun Mai
Te‐Lun Mai
YLYing‐Chung Jimmy Lin
Ying‐Chung Jimmy Lin
Yu-Ju ChenYu-Ju Chen
Yu-Ju Chen
SKShang‐Che Kuo
Shang‐Che Kuo
JSJung‐Chen Su
Jung‐Chen Su
Phenotypic drug discovery (PDD) is an effective drug discovery approach by observation of therapeutic effects on disease phenotypes, especially in complex disease systems. Triple‐negative breast cancer (TNBC) is composed of several complex disease features, including high tumor heterogeneity, high invasive and metastatic potential, and a lack of effective therapeutic targets. Therefore, identifying effective and novel agents through PDD is a current trend in TNBC drug development. In this study, 23 novel small molecules were synthesized using 4‐(phenylsulfonyl)morpholine as a pharmacophore. Among these derivatives, GL24 (4m) exhibited the lowest half‐maximal inhibitory concentration value (0.90 µM) in MDA‐MB‐231 cells. To investigate the tumor‐suppressive mechanisms of GL24, transcriptomic analyses were used to detect the perturbation for gene expression upon GL24 treatment. Followed by gene ontology (GO) analysis, gene set enrichment analysis (GSEA), and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, multiple ER stress‐dependent tumor suppressive signals were identified, such as unfolded protein response (UPR), p53 pathway, G2/M checkpoint, and E2F targets. Most of the identified pathways triggered by GL24 eventually led to cell‐cycle arrest and then to apoptosis. In summary, we developed a novel 4‐(phenylsulfonyl)morpholine derivative GL24 with a strong potential for inhibiting TNBC cell growth through ER stress‐dependent tumor suppressive signals.